The Race to Delete a Protein and Treat Rheumatoid Arthritis
Evommune is licensing a VAV1 molecular glue degrader from China's Hinova to chase JAK-like efficacy in rheumatoid arthritis without the class's boxed safety warnings.
Rheumatoid arthritis's three branded oral JAK inhibitors all carry the same FDA boxed warning, and it has reshaped how the disease is treated. Evommune (Nasdaq: EVMN) is paying for a different approach: destroy a lymphocyte signaling protein outright, rather than inhibit a kinase that is expressed across many tissues.
On Nov. 4, 2026, Evommune announced it had licensed EVO570, an oral VAV1 molecular glue degrader, from Hinova Pharmaceuticals (Shanghai: 688302). The mechanistic pitch is straightforward. VAV1 sits downstream of the T-cell and B-cell receptors and is expressed mainly in immune cells, while JAK enzymes are not. The commercial opening is larger. If a VAV1 degrader can deliver JAK-like efficacy without the class safety label, it would reopen oral rheumatoid arthritis for patients who now have to fail a TNF blocker first. The catch is timing. EVO570 has not dosed a Phase 1 patient, and Evommune is buying the program after its last oral lead failed twice.
After two misses, a license worth up to $1.1 billion
A prospectus sets the terms. Evommune is paying $30 million upfront, split as $20 million in cash plus $10 million in pre-funded warrants covering 1,262,413 shares. Development and regulatory milestones can add up to $150 million, and commercial milestones up to $920 million, or about $1.07 billion in total (roughly $1.1 billion), plus tiered royalties in the mid-single to low-double digits. Rights are worldwide except Greater China, meaning mainland China, Hong Kong, Macau, and Taiwan.
Evommune also raised a concurrent $30 million private placement at $6.04 per share (4,966,889 shares), expected to close on or about Nov. 6, 2026. Pro forma cash and investments are roughly $292.3 million, a runway the company says should fund operations into the second half of 2029.
That cash is plugging a hole. Evommune's prior oral lead, EVO756, an MRGPRX2 antagonist, missed its primary endpoint in two Phase 2b trials, in chronic spontaneous urticaria and atopic dermatitis, and development in both indications was discontinued.
The case for deleting VAV1
EVO570 is a molecular glue degrader. It recruits the cereblon (CRBN) E3 ligase to tag VAV1 for destruction by the cell's proteasome, eliminating the protein rather than merely inhibiting it. VAV1 (Vav guanine nucleotide exchange factor 1) is a signaling protein that drives lymphocyte activation. Because it is expressed mainly in immune cells, whereas JAK enzymes are expressed broadly across tissues, the rationale is JAK-class immune suppression with less off-tissue exposure.
That rationale exists because the oral rheumatoid arthritis market is constrained by safety, not by a shortage of JAK drugs. The JAK inhibitors tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq) are the three in question. On Sept. 1, 2021, based on the ORAL Surveillance trial, the FDA required boxed warnings for serious heart-related events, cancer, blood clots, and death, and limited use to patients who fail or cannot tolerate TNF blockers.
Evommune chief scientific officer Jeegar Patel described EVO570 as having sub-nanomolar potency, high selectivity, and a profile supporting once-daily oral dosing, with the potential for what he called "JAK-like efficacy without the safety and tolerability challenges" of other therapies.
A Phase 2 rival, and no patients yet
Evommune is late to its own race. Novartis licensed Monte Rosa Therapeutics' VAV1 molecular glue degrader MRT-6160 in October 2024 for $150 million upfront plus up to $2.1 billion in milestones, and has advanced it into Phase 2 for psoriatic arthritis and Sjogren's disease. Hinova has claimed roughly 20-fold greater in vitro potency than MRT-6160, but that figure comes from Hinova's own preclinical data and is not independently confirmed.
There are more than 1.2 million rheumatoid arthritis patients in the US. EVO570's US investigational new drug application is accepted. A Phase 1 trial is expected to begin imminently, with a Phase 2 in rheumatoid arthritis planned for 2027.
The biology is elegant, and the clinical file is empty. EVO570 is still preclinical. The IND is accepted, but no Phase 1 patient has been dosed yet. William Blair analysts noted that VAV1 has had difficulty with selectivity historically, which is the old reason this target sat on the shelf. Destroying the protein with a glue may solve that, or it may recreate it in a new form.
If VAV1 degradation can match JAK-level efficacy without the boxed warning, oral rheumatoid arthritis gets a new class. Evommune now has the license, a 2029 cash runway, and a 2027 Phase 2 plan. What it does not have is human data, and Novartis already does.
